Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices

NCT07596186 · tracked via the Priya Life Science Israel tracker
Phase
Observational
Started
2024-12-01
Last updated
2026-05-19

Condition(s) studied

Cognitive Decline, Mild

Study summary

The study will recruit 100 participants aged 65+ residing in assisted living facilities. Eligible participants will undergo an initial cognitive assessment to document their baseline cognitive status using cognitive tests conducted either in their assisted living facility or at Soroka Medical Center. An app designed for research data collection (Aware-Light) will be installed on participants' mobile devices, collecting data only after participants provide consent. Over three months, the app will automatically gather sensor data, including movement data from the accelerometer, orientation data from the gravity sensor, rotation data from the gyroscope, proximity data for measuring distance from nearby objects, ambient light levels from the light sensor, and typing dynamics such as typing frequency and duration without recording actual text. The app will also track app usage, including activation, pauses, closures, background activity, notifications, and crashes, as well as air pressure through the barometer, phone capabilities through the telephony detector, and screen states such as on, locked, or off. It will log communication events such as calls and messages without recording personal details, monitor vehicle speed through the linear accelerometer, track rotation angles through the rotation detector, and identify significant movements like walking, cycling, or traveling. No typed data, such as passwords, will be collected. After one month, the research team will contact participants to ensure the app functions correctly. After three months, participants will undergo a second cognitive assessment, and the app will be uninstalled.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age 65 and over * Clalit HMO members. * Without a known diagnosis of dementia * Uses Android mobile phones and writes text messages Exclusion Criteria: * A known diagnosis of dementia * Uses IOS mobile. * Doesn't write text messages

Primary outcome measure(s)

  • Prediction model of mobile device data, collected for 9 months of lower scores in Neurotrax cognitive assessment compared to baseline evaluation. — Baseline and 9 Month after
    Mobile device sensor data

Trial sites (1)

FacilityCityRegionStatus
Soroka Medical Center Beersheba Israel
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07596186 on ClinicalTrials.gov ↗ ← All trials in Israel